Site Search

Menu

Events (de)

Loading Results

2025 Outlook: Austrian Perspective

Global M&A Trends in Health Industries
Global M&A Industry Trends in Health Industries hero image
  • Insight
  • 8 minute read
  • January 28, 2025

Global M&A Trends in Health Industries for 2025: A Challenging Yet Promising Dealmaking Environment

Christian K. Moldt

Christian K. Moldt

Global Health Industries Deals Leader, PwC Germany

Email

Portfolio gaps, supply chain uncertainty, changes in policy direction and other fundamental factors are expected to drive M&A by health industries companies in 2025. We believe a stronger US and European deal market, spurred by improving macroeconomic factors and the expectation of lighter US regulation, will lead to accelerated deal values and volumes over the next year.

In the pharmaceuticals and life sciences sector, large-cap pharma companies are looking to acquire innovative late-stage biotech companies to help further differentiate their portfolios and reposition for growth. For example, in July 2024 Biogen acquired Human Immunology Biosciences; in August 2024 Eli Lilly acquired Morphic and in January 2025 Johnson & Johnson announced their proposed acquisition of Intra-Cellular Therapies. 

With Big Pharma facing a significant drop in revenue over the next few years due to imminent patent cliffs, we expect them to undertake acquisitions to fill gaps in their portfolios, focus attention on targeted therapeutic areas and aim for greater innovation in select products. This also includes gaining entry into emerging areas. In addition, we expect them to continue to evaluate divestments of lower-growth or non-core assets that compete for internal management attention and resources. Examples of this divestiture strategy include Viatris’ sale of its over-the-counter business to Cooper Consumer Health, its active pharmaceutical ingredients division to Matrix Pharma Private and its women’s health business to Insud Pharma.

In the healthcare services sector, companies will continue to acquire digital assets or technology companies, including the exploration of AI-enabled services, to deliver a cost-effective high standard of care. Recent examples include Cantata Health Solutions’ acquisition of Geisler IT Services and Cardinal Health’s acquisition of Specialty Networks and its PPS Analytics platform.

Private equity (PE). PE still has significant capital it is looking to deploy and a growing pipeline of potential divestiture candidates, as funds reach the end of their holding period. In the PE community, interest in medtech and digital health companies is rising, as illustrated by the February 2024 acquisition by KKR of a 50% stake in Cotiviti, a healthcare data and technology business, or the proposed acquisition by TowerBrook and CD&R of R1 RCM, a provider of technology-driven solutions to the healthcare industry. This trend will likely last through 2025, with exciting targets expected to come to market. In health services, legislative headwinds, funding cuts, and overall yields below expectations will affect valuations and investment decisions, particularly in clinics and medical service centres or group practices in certain geographies.

As we step into 2025, the global healthcare sector is poised for a more favourable M&A environment, bolstered by improving macroeconomic conditions, potential regulatory relaxations, and increased investor interest. However, various factors continue to introduce uncertainty.

In pharmaceuticals and life sciences, large pharmaceutical companies are expected to focus on acquiring late-stage biotech firms to strengthen their portfolios, driven by ongoing patent cliffs and the need for innovation. These acquisitions will be more strategic compared to previous years, with a sharper focus on targeted therapeutic areas rather than broad expansions. Furthermore, large pharmaceutical conglomerates will continue monitoring their portfolios for non-core assets and other low-growth areas as divestiture candidates.

The healthcare services sector, particularly the digital health technologies, will remain an interesting target, as demand for AI-driven solutions grows. Legacy healthcare providers will continue to use M&A to access technological innovations to help deliver care, including AI and analytics technology, telemedicine platforms, smart health devices and other software innovations. 

Private equity remains a significant force in healthcare M&A, although investors are likely to proceed more cautiously in 2025, given uncertainties around valuations and market volatility. While sectors like MedTech and Digital Health continue to attract attention, PE firms are expected to pursue investments with more predictable outcomes, likely favouring targeted, lower-risk opportunities over larger, high-risk ventures.

‘I am increasingly, but still cautiously, optimistic about the M&A market in 2025 across health industries. I see signs of a growing pressure to act among dealmakers. Declining interest rates and an anticipated easing of regulations will create a more deal-friendly environment.’

Christian K. Moldt,Global Health Industries Deals Leader, PwC Germany

Dealmaking obstacles. There is growing optimism that some obstacles impeding dealmaking in recent years are subsiding as global interest rates fall back amid signs in the US that antitrust regulators may adopt a more relaxed stance to mergers in general under the new administration; however, it remains to be seen whether this will indeed be the case, and to what degree it could affect pharma and other healthcare players.

IPO markets. With activity in the initial public offering (IPO) market expected to pick up in 2025, this will unlock additional sources of capital and funding. A number of companies are preparing to go public, both in the US and in other jurisdictions. In late 2024, a growing number of pharmaceutical and life sciences companies confidentially filed their IPO registration documents with the US Securities and Exchange Commission, indicating their intention to go public in 2025. Outside the US, several other companies have announced plans to go public, including Polish medical diagnostic company Diagnostyka, Swiss clinical-stage biotechnology company Topadur and Swiss company Xlife Sciences, which announced plans to separately list its portfolio company, Veraxa Biotech, on the US Nasdaq stock market in 2025.

86%

of health industries CEOs who made a significant acquisition in the past three years plan to make one or more acquisitions in the next three years.

Source: PwC’s 28th Annual Global CEO Survey, January 2025

Global M&A Hotspots in 2025: Strategic Focus and Areas of Caution

Several sectors are poised for M&A activity in 2025, albeit with a cautious outlook:

As large pharmaceutical companies face patent cliffs, their focus will be on acquiring late-stage biotech firms to fill portfolio gaps. While this will drive activity, the volume of large deals is expected to decrease. Investors will prioritize assets with clearer market potential, particularly late-stage products that can be quickly brought to market.

Digital health remains a priority, with selective acquisitions activity expected to increase in 2025. However, regulatory challenges and integration complexities could dampen the overall pace of dealmaking in the sector. The emphasis on cost-effective, value-based care will continue to fuel interest in AI and telemedicine solutions.

Transformative deals are emerging as recently spun-off or divested pure-play over the counter (OTC) and consumer health businesses look to accelerate their transformation through M&A. We expect large conglomerates to continue evaluating their portfolios, separating lower-growth or non-core businesses from more innovative, high-growth areas. Additionally, we foresee a strong pipeline of private equity-owned businesses in this sector entering the market in 2025, potentially fueling further innovation and strategic investment in consumer healthcare.

Alternative transaction structures, such as joint ventures, partnerships, and collaborations, are expected to increase, reflecting the need for flexible dealmaking approaches. Overall, M&A activity is likely to be restrained, with fewer megadeals compared to previous years.

The Austrian Perspective: Local Challenges and Impact on M&A Activity

In 2024, the number of M&A deals in Austria's healthcare sector saw a decrease compared to the previous year, which had an above-average number of deals, indicating a trend towards more selective investments. Notable transactions in 2024 include Ligand Pharmaceuticals' acquisition of APEIRON Biologics for USD 100 million, providing Ligand with the opportunity to expand its portfolio in immunotherapies and biologics as well as ROHTO Pharmaceutical's purchase of 51% of Sigmapharm’s parent company for USD 33 million, aimed at expanding production and strengthening its European market presence.

The Austrian healthcare market in 2025 presents a challenging environment shaped by macroeconomic uncertainties and complex regulatory dynamics. However, there are opportunities for targeted M&A activity, particularly amidst ongoing digital health reforms, which are expected to drive strategic growth in the sector.

Austria as a Life Science Innovation Hub

Austria has long been a hub for biotech and MedTech innovation, with a strong R&D base and a vibrant startup ecosystem. These sectors will likely remain of interest to investors in 2025, though the overall deal volumes will likely be moderate compared to previous years. The focus will be on strategic partnerships and acquisitions within digital health and MedTech rather than large-scale transactions. Despite competition, Austrian companies offering innovative solutions in these areas will continue to attract both local and international investors.

Health Reforms and Digital Health: Opportunities with a Slow Pace

Digital health reforms, aimed at modernizing Austria's healthcare infrastructure, will present some potential opportunities, particularly in areas like eHealth, telemedicine, and medical imaging. However, the pace of these reforms is expected to be slow, and the regulatory environment remains complex, which may dampen the speed at which investments and acquisitions take place. Still, companies in these areas could see growing demand, especially as digital health solutions become more integrated into the national healthcare system.

Regulatory Challenges and the Impact on M&A Activity in Healthcare

Despite opportunities, Austria's regulatory landscape remains challenging. Restrictions on the privatization of healthcare facilities and hospitals limit significant transactions in this field. Nevertheless, there could be opportunities for smaller, more focused acquisitions, particularly in areas where digital health solutions and innovations align with the country's reform goals.

In conclusion, while the Austrian healthcare sector faces challenges in 2025, there are still opportunities for strategic growth. The pace of M&A activity will likely remain cautious, with a focus on smaller, more targeted deals. Despite the overall market being restrained by external factors, Austria's strong innovation landscape and the ongoing push for digital transformation provide a foundation for selective, albeit moderate, growth in the sector.

Spotlight on biotech

Large-cap pharma companies continue to face patent cliffs and gaps in their drug pipelines and will look for M&A opportunities to fill these gaps and achieve their growth plans. For years, investing in time-intensive research with uncertain outcomes and significant time to market was not the priority for big pharma; rather, the strategy has been to fill the pipeline through biotech integrations and bolt-on deals of assets with a more certain study outcome and market potential. Midsize biotech companies with strong revenue potential are likely to receive significant attention in 2025, with those companies with drugs in Phase III trials that could come to market relatively quickly likely to receive the most attention versus those in earlier stages.

Biotechnology M&A trends have evolved significantly since the pandemic. From 2019 to 2020, investments surged by 128%, followed by growth in minority investments from PE firms, which reached a peak in 2022. A shift occurred in 2022, as full acquisitions by strategic players (takeover deals) once again outpaced minority investments and returned to pre-2020 trends. PE firms and other financial investors have subsequently scaled back their involvement in the industry. This shift has influenced the focus of investments: partial acquisitions were primarily directed at companies in the early stages of drug development (Phase I and early-stage Phase II), whereas full acquisitions targeted companies with products in later stages of development (late-stage Phase II or Phase III) or those with recently approved drugs. In contrast, venture capital investments and collaborations in biotechnology generally focus on companies with preclinical products.

Oncology remains a dominant therapeutic area, representing nearly 40% of deals and 45% of funds invested. US companies dominate M&A activity, with 80% of targets and 60% of acquirers based there. Besides PE and large pharma companies, other biotech firms and medium-sized pharmaceutical companies also invested. For example, many of the large pharma companies are adopting a science-led portfolio-driven approach to their pipeline. Although 2024 saw a slowdown in biotech deals, the numbers remain high compared to other subsectors.

Investors might continue to be more cautious, but large pharmaceutical companies still need to expand their portfolios and find new revenue sources, leading to a promising market outlook for the 2025 biotech deal landscape. However, we expect this will be characterised by smaller deals as compared to the record deal values observed in the past (based on individual deal value), while large pharmaceutical companies are likely to access highly valued assets by employing more innovative strategies, such as collaborations, alliances, or joint ventures.  Consequently, and in contrast to the broader M&A market trend of increasing momentum in megadeals, we anticipate seeing less health industries megadeals activity in 2025 than during 2024 and 2023.

Other M&A hot spots in 2025

In addition to biotech, we expect that portfolio optimisation, GLP-1s, telehealth, healthtech, health analytics and consumer healthcare will be hot spots for M&A activity in health industries in 2025:

  • Divesting non-core assets and portfolio optimisation: Large pharmaceutical conglomerates will continue monitoring their portfolios for non-core assets and other low-growth areas as divestiture candidates. These divestitures can be used to generate cash to fund new investments in an effort to optimise portfolios, more closely align with their core competencies, and provide balance-sheet relief, by offloading R&D expense and reducing complexity along the supply chain from manufacturing through distribution.
  • GLP-1s and the cardiometabolic market: Growth in the industry has been largely concentrated in the GLP-1 market, as highlighted in our 2024 mid-year M&A outlook. Established players such as Novo Nordisk and Eli Lilly, as well as newcomers to the field, may consider M&A as a strategy for growth. Through M&A, they can gain access to the limited global production capacities for both active pharmaceutical ingredients (APIs) and finished products. This is particularly important because the oral-dosage forms require more APIs compared to injectable forms. In addition, as new therapies are expected to come to the market, we expect the leading drugs to be increasingly challenged, putting even more pressure on the established GLP-1 players to expand capacities and develop their portfolios. Meanwhile, global demand for these products is expected to continue rising steeply.
  • Filling in value gaps with digital innovation: Staffing challenges, inflationary cost bases and stagnant government funding continues to put pressure on healthcare providers to find digital efficiencies that can help bridge the gap. Telehealth, healthtech and health analytics companies that help deliver greater efficiencies in providing patient care will continue to be attractive assets to invest in.
  • Transformative deals in consumer healthcare: Recently spun-off or divested pure-play over-the-counter (OTC) and consumer health businesses are expected to seek to accelerate their own transformation plans via M&A. Sanofi’s decision to transfer a controlling stake in its consumer health business, Opella, to CD&R, instead of a spin-off IPO, allows Sanofi to remain a significant shareholder, while partnering with a PE firm with experience in the consumer space who will support Opella’s future growth strategy. Viatris pursued a similar path in the sale of its over-the-counter assets to CVC-backed Cooper Consumer Health. We expect large conglomerates will continue to review portfolio opportunities to separate lower-growth or non-core businesses from more innovative and higher-growth areas. In addition, we expect a robust pipeline of PE-owned business in this sector to come to market in 2025.

Key M&A themes for health industries in 2025

  • Multinational companies seeking avenues for cross-border investment: Companies are preparing for the possibility of disruptions to cross-border supply chains, and consequently to their revenue, from a range of actions including the potential for increased tariffs in the US and volume-based procurement in China. They are also bracing for the possibility that lawmakers could pursue policies to repatriate drug manufacturing onshore or nearshore. This may result in deals looking to onshore manufacturing activity or find creative partnerships and licensing deals to sell through to international markets such as China. We expect companies to look for M&A investment solutions to resolve cross-border operating challenges.
  • The search for capital: Interest rates are beginning to decline globally, stock indices at an all-time high in some markets and signs of life are appearing in the previously quieter IPO market. As such, we expect health industry companies to explore IPO options and pursue additional funding for M&A activity, as well as to secure access to innovative R&D research funnels.
  • Alternative deal structures and collaborations: Even with the cost of capital coming down, we observe an increasing number of alternative deal structures and more creative ways of securing access to pipeline assets, through joint ventures, licensing or collaboration models. One recent example is Bayer’s expanding global life science incubator network, in which promising startups can benefit from state-of-the-art facilities and mentorship.
  • Divesting non-core and low-growth assets: Companies will continue to strategically evaluate and identify non-core and margin-dilutive assets for divestment, sometimes in response to significant pressure from shareholder activists. This continues a trend we have been observing in the market for some time, highlighted by the recent series of divestments by Viatris and Sanofi noted earlier. The proceeds from the recent large-scale sale of Haleon shares by GSK and Pfizer will offer these companies financial flexibility, allowing them to reduce debt or invest in areas closely aligned with their strategic objectives.
  • Theoretical M&A capacity: Divestiture proceeds helped mitigate an approximate 21% decline in theoretical M&A capacity between 2022 and 2024, with 2024 showing some slight improvement over the prior year. We calculated the theoretical M&A capacity of a sample of large pharmaceutical companies, by referencing the viable ratio of leveraged financing in relation to their EBITDA and net debt. In our calculations we applied an industry average of 3x Debt-to-EBITDA ratio to the company’s earnings and subtracted their net debt.
  • Acquiring digital avenues to cost-effective value-based care: Legacy healthcare providers will continue to use M&A to access technological innovations to help deliver care, including AI and analytics technology, telemedicine platforms, smart health devices and other software innovations. Faced with continuously rising labour costs and staffing shortages these companies will seek to drive down operating costs while also shifting towards patient-centred, value-based care. Acquiring or partnering with data and analytics and other technology companies will help deliver these digital solutions. 

Global M&A volumes and values in health industries declined between 2023 and 2024 by 20% and 29%, respectively. Pharma and life sciences deal volumes decreased by 18%, but values decreased more significantly by 31% due to fewer megadeals (deals greater than $5bn)—with ten megadeals in 2023, down to two in 2024. Healthcare services deal volumes and values declined by 22% and 21%, respectively.

Key actions for health industries dealmakers in 2025

With an ever-persistent business need to get deals done to stay competitive, health industries companies that proactively build the capabilities to acquire, divest and integrate the right assets will outperform the rest of the sector. As the macro and regulatory environment that has slowed health industries dealmaking in recent years begins to improve, dealmakers should be ready to act quickly on innovative assets when they hit the market. The further development of interest rates should be watched closely as well as policy changes arising from the new US administration. In particular, the anticipated easing of regulations may provide a tailwind to pharma and health industries dealmaking, not just in the US, but also globally. Health industries leaders who are already thinking several steps ahead and can successfully navigate remaining uncertainties will have a significant opportunity in 2025 to use M&A to transform their businesses for success.

Our commentary on M&A trends is based on data from industry-recognised sources and our own independent research. Specifically, deal values and volumes referenced in this publication are based on officially announced transactions, excluding rumoured and withdrawn transactions, as provided by the London Stock Exchange Group (LSEG) as of 31 December 2024 and as accessed between 6–9 January 2025. This has been supplemented by additional information from S&P Capital IQ, company filings and our independent research. Certain adjustments have been made to the source information to align with PwC’s industry mapping. All dollar amounts are in US dollars. Megadeals are defined as deals greater than $5bn in value. 

The theoretical M&A capacity calculation is based on the differential between net debt and EBITDA-based total debt capacity. The calculation for 2024 is an estimate made using company websites and filing information through June 2024 as a proxy for the full year.

Christian K. Moldt is PwC’s global health industries deals leader and PwC’s EMEA health industries leader. He is a partner with PwC Germany. André Sassmannshausen is a director with PwC Germany. Mike Proppe is a director with PwC US. Both André and Mike work in PwC’s health industries deals team.

Explore our local M&A Trends in Health Industries from the following countries or regions:

Explore the other insights in our Global M&A Industry Trends series

Global M&A industry trends Consumer Markets Energy, Utilities & Resources Financial Services Industrials & Services Private Capital Real Estate Technology, Media & Telecommunications

Required fields are marked with an asterisk(*)

By submitting your email address, you acknowledge that you have read the Privacy Statement and that you consent to our processing data in accordance with the Privacy Statement (including international transfers). If you change your mind at any time about wishing to receive the information from us, you can send us an email message using the Contact Us page.

Michael Lind

Managing Partner, PwC Legal*

+43 664 967 86 60

Email

Amra Ibric

Pharma & Life Sciences, PwC Austria

+43 676 3329 322

Email

Services Industries Issues About us Careers Newsletter (de) Publications (de) Events (de)

© 2017 - 2025 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.